Medication-assisted Treatment (MAT) Market - Top Companies and Manufacturers

Companies Dominating the Medication-assisted Treatment Landscape

Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Mallinckrodt Pharmaceuticals
Titan Pharmaceuticals, Inc.
Alkermes plc
Orexo AB
Mylan N.V.
Teva Pharmaceuticals Industries Ltd.
Lupin limited
Hikma Pharmaceuticals PLC
Novartis AG

Browse Key Market Insights with Data Illustration:

Medication-assisted Treatment (MAT) Market Size & Share, Growth Trends 2036

In the News

December 2023: Alkerems plc announced that it entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk , a leading global healthcare company. In terms of agreement, Alkermes will be entitled to one time cash payment of USD 92.5 Million for the facility and related assets, subject to customary adjustments in accordance with the agreement. In addition, Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing the transaction, which may continue through the end of 2025.
August 2023: Orexo AB announced that it continues to strengthen its patent portfolio and the new patent , No. US 11,737,980 provides protection for the OX640 product in the US until may 2041. Moreover, Orexo’s proprietary drug delivery platform , amorphOX, is a powder made up of particles which are built using a unique combination of drug, carrier materials and optionally other ingredients.

Frequently Asked Questions (FAQ)

Increase in substance abuse deaths, rising awareness of Medical â€“assisted Treatment (MAT) and emergence of technological innovations are the major factors driving the growth of the medication-assisted treatment market.

The market size of medication-assisted treatment is anticipated to attain a CAGR of 11.4% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Orexo AB, Novartis AG, Mylan N.V., Lupin Limited, Hikma Pharmaceuticals PLC and others.

The drug type segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Medication-assisted Treatment (MAT) Market - Top Companies and Manufacturers

Companies Dominating the Medication-assisted Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the medication-assisted treatment market?

What would be the CAGR of the medication-assisted treatment market over the forecast period?

Who are the major players dominating the medication-assisted treatment market?

Which segment captures the largest market size in the treatment type segment in the medication-assisted treatment market?

Which region will provide more business opportunities for the growth of the medication-assisted treatment market in the future?